Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD (DEFEND) Clinical Trial

NCT06792214 is registered in ClinicalTrials.gov with Mount Sinai Hospital, Canada as lead sponsor.

NCT NCT06792214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06792214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD (DEFEND) Clinical Trial
Lead sponsor
Mount Sinai Hospital, Canada
Phase
Phase 4
Overall status
Recruiting
Start date
January 3, 2025
Completion date
January 31, 2027
Enrollment
118 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sars cov-2 post-acute sequelae